Tumor-specific draining lymph node CD8 T cells orchestrate an anti-tumor response to neoadjuvant PD-1 immune checkpoint blockade

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

PD-1 immune checkpoint blockade (ICB) with platinum chemotherapy (ChemoIO) has transformed treatment for resectable non-small cell lung cancer (NSCLC). PD-1 ICB was established and created to reinvigorate tumor T cells and reduce T cell exhaustion. However, the impact of PD-1 blockade on the induction and maintenance of tumor-relevant tdLN T cells and functional T cell memory in the context of surgical resection is not fully understood. We hypothesized that T cells activated in the tumor draining lymph node (tdLN) also respond to PD-I ICB. We assessed clonal dynamics of tumor-specific tdLN T cell clones by using single-cell TCR barcoding integrated with transcriptional profiling (scRNA sequencing) by using machine learning (ML) and bioinformatic approaches. We displayed that within the tumor tdLN-paired clones were less exhausted than clones not clonally linked to the tdLN. We established that there are two distinct LN-paired anti-tumor clonal populations: those that directly link from the tdLN and tumor (tdLN-tumor paired) with tumor killing capacity, and clones that circulate within the blood with cytotoxic memory surveillance potential. Furthermore, the transcriptional distinction of these two LN-paired subsets was set in the earliest memory state of expanded tumor-specific tdLN T cells and reflected in the tumor as similarly, more differentiated, effector subsets. ChemoIO was also found to directly impact tdLN-paired clonal diversity and memory phenotypic differentiation. Finally, our findings demonstrate that ChemoIO is enhancing the cytotoxic function of circulating LN-paired clones in the tdLN and subsequently also altering circulating blood LN-paired clonal phenotype. Together our results established that tumor-relevant T cells are transcriptionally altered by PD-1 ICB locally in the tdLN and provide evidence that lymph node derived T cells are a primary source of anti-tumor immunity in surgically resectable NSCLC.

Article activity feed